Age Found to Be Main Driver of MS Disability, Patient Therapy Response

Age Found to Be Main Driver of MS Disability, Patient Therapy Response

284446

Age Found to Be Main Driver of MS Disability, Patient Therapy Response

Age is a main driver of disability in multiple sclerosis (MS) and has a key influence on patients’ therapeutic responses to Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), a study showed. Given those findings, age should be considered in the risk/benefit assessment that’s used in the decision-making process for choosing MS treatments, the researchers suggested. The study, “The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis,” was published in the…

You must be logged in to read/download the full post.